Arbovirus Testing Market Size, Share & Industry Analysis, By Type (ELISA-Based Tests, RT-PCR Based Tests), By End-Use (Diagnostic Laboratories, Hospitals, Research Centers) and Regional Forecast, 2026-2034

The Arbovirus Testing market size was valued at USD 1.19 Billion in 2025. The market is projected to grow from USD 1.24 Billion in 2026 to USD 1.77 Billion by 2034, exhibiting a CAGR of 4.58% during the forecast period.

The Arbovirus Testing Market covers diagnostic products, assays, platforms, reagents, and laboratory services used to detect infections transmitted by mosquitoes, ticks, and other arthropod vectors. Key targets include dengue, Zika, chikungunya, West Nile virus, yellow fever, Japanese encephalitis, and related viral infections. The Arbovirus Testing Market is shaped by rising outbreak surveillance, climate-linked vector expansion, travel-associated infections, and growing demand for early molecular and serological diagnosis. Arbovirus Testing Market Report buyers increasingly seek validated ELISA-based tests, RT-PCR based tests, multiplex panels, and laboratory workflows that support clinical decision-making and public health monitoring.

The USA Arbovirus Testing Market is supported by strong public health surveillance, hospital-based testing, reference laboratory networks, and increasing travel-associated dengue and chikungunya investigations. West Nile virus remains a major domestic testing driver, while dengue and Zika testing demand rises during travel seasons and outbreak alerts. U.S. hospitals, diagnostic laboratories, and research centers use arbovirus testing for acute diagnosis, confirmatory testing, epidemiological tracking, and blood safety support. Arbovirus Testing Market Analysis in the USA highlights demand for faster turnaround, improved assay specificity, and integrated platforms that distinguish overlapping febrile illnesses with similar clinical symptoms.

Key Takeaways

Market Size & Growth

• Global market size 2025: USD 1.19 Billion
• Global market size 2034: USD 1.77 Billion
• CAGR (2025–2034): 4.58% 

Market Share – Regionals

• North America: 36% 
• Europe: 27%
• Asia-Pacific: 29% 
• Rest of World: 8%

Country-Level Shares

• Germany: 24% of Europe’s market 
• United Kingdom: 19% of Europe’s market
• Japan: 17% of Asia-Pacific market 
• China: 33% of Asia-Pacific market

Arbovirus Testing Market Latest Trends

The Arbovirus Testing Market Trends are moving toward multiplex molecular diagnostics, automated serology platforms, and outbreak-ready testing models. Laboratories increasingly prefer workflows that can differentiate dengue, Zika, chikungunya, and West Nile virus from other febrile illnesses using the same sample pathway. This is especially important because early symptoms overlap with influenza, malaria, leptospirosis, COVID-like respiratory illness, and other tropical infections. Demand for Arbovirus Testing Market Research Report insights is rising among hospitals, diagnostic laboratories, public health agencies, and manufacturers seeking better product positioning.

Download Free sample to learn more about this report.

Another important trend is the wider use of RT-PCR testing during the early acute phase of infection, followed by ELISA-based IgM and IgG testing for later-stage confirmation. The Arbovirus Testing Industry Report also reflects growing interest in point-of-care screening, sample-to-answer molecular systems, and digital laboratory reporting. Climate variability, urbanization, mosquito habitat expansion, and increased international travel are pushing governments to strengthen surveillance systems. B2B customers are prioritizing validated kits, stable reagent supply, scalable automation, and regulatory-ready documentation. These shifts are making Arbovirus Testing Market Outlook more focused on speed, specificity, and preparedness.

Arbovirus Testing Market Dynamics

DRIVER

Rising Burden of Mosquito-Borne Viral Infections

The main driver of Arbovirus Testing Market Growth is the increasing burden of mosquito-borne viral infections across endemic and non-endemic regions. Dengue, Zika, chikungunya, and West Nile virus continue to create testing demand because they require reliable diagnosis for patient management, outbreak response, blood donor screening, travel medicine, and epidemiological reporting. Many arboviruses produce similar symptoms, including fever, rash, joint pain, headache, and fatigue, which makes clinical diagnosis alone unreliable. As a result, healthcare providers increasingly depend on ELISA-based tests and RT-PCR based tests to confirm infection and differentiate viral causes.

The Arbovirus Testing Market Size is also influenced by stronger disease surveillance programs. Public health agencies need diagnostic data to detect clusters, monitor seasonal transmission, and guide mosquito-control activities. Hospitals and diagnostic laboratories are expanding arbovirus testing menus to serve travelers, pregnant patients, immunocompromised populations, and residents in regions where vectors are expanding. For B2B buyers, the need for dependable assay performance, rapid turnaround, and scalable supply has made arbovirus diagnostics a strategic investment area.

RESTRAINT

Cross-Reactivity and Diagnostic Complexity

A major restraint in the Arbovirus Testing Market is diagnostic complexity caused by cross-reactivity among related viruses. Dengue, Zika, West Nile virus, Japanese encephalitis, and yellow fever belong to closely related viral families, and antibody-based tests may produce overlapping immune responses. This makes interpretation difficult, especially in patients with previous infection, vaccination history, or exposure to multiple flaviviruses. Laboratories often need confirmatory testing, paired samples, or molecular methods to improve accuracy, which increases workflow burden.

The Arbovirus Testing Industry Analysis also shows that resource-limited settings may struggle with advanced laboratory infrastructure, trained personnel, cold-chain management, and reagent availability. RT-PCR based tests require specialized equipment and quality-controlled workflows, while ELISA-based tests require careful timing based on symptom onset. In many regions, delayed testing, limited reimbursement, and fragmented surveillance systems can reduce adoption. These barriers affect Arbovirus Testing Market Share distribution because high-capacity laboratories gain an advantage over smaller facilities that cannot maintain broad arbovirus testing panels year-round.

OPPORTUNITY

Expansion of Multiplex and Point-Of-Care Diagnostics

The strongest Arbovirus Testing Market Opportunities are linked to multiplex testing and near-patient diagnostics. Healthcare providers need tools that can detect multiple arboviruses in one workflow, especially during outbreaks where dengue, Zika, and chikungunya may circulate together. Multiplex RT-PCR panels, automated ELISA systems, and rapid immunoassays can help laboratories reduce turnaround time and improve diagnostic confidence. Manufacturers that combine sensitivity, specificity, ease of use, and scalable production can capture strong B2B demand.

The Arbovirus Testing Market Forecast is also supported by investment in decentralized diagnostics. Smaller hospitals, mobile clinics, travel health centers, and regional laboratories need practical tools that do not depend fully on centralized reference testing. Point-of-care and cartridge-based platforms can improve outbreak readiness in tropical and subtropical regions. Research centers are also creating demand for surveillance-grade assays, sequencing-compatible workflows, and vector-testing solutions. These opportunities create space for companies offering integrated product portfolios, technical training, and strong distributor networks.

CHALLENGE

Seasonal Demand Fluctuation and Outbreak Unpredictability

A major challenge in the Arbovirus Testing Market is unpredictable demand. Arbovirus outbreaks often vary by season, rainfall, temperature, mosquito density, travel patterns, and public health response. Manufacturers and laboratories must prepare for sudden spikes in test demand while avoiding excess inventory during low-transmission periods. This creates planning pressure for assay suppliers, reagent manufacturers, distributors, and diagnostic laboratories.

Another challenge is maintaining test accuracy across changing viral strains and geographic variations. Arboviruses can spread into new regions, requiring laboratories to update testing algorithms and validate assays against locally relevant pathogens. B2B buyers expect consistent supply, regulatory compliance, technical support, and performance data across diverse use cases. The Arbovirus Testing Market Insights indicate that companies must balance innovation with reliability. Products that are difficult to interpret, slow to deliver, or poorly integrated into laboratory workflows may lose competitiveness even if they have strong technical performance.

Arbovirus Testing Market Segmentation

By Type

ELISA-based tests hold an estimated 49% share of the Arbovirus Testing Market. This segment remains important because ELISA platforms are widely used for detecting IgM and IgG antibodies after the early acute phase of infection. ELISA-based tests are especially valuable for dengue, Zika, chikungunya, West Nile virus, and other arboviruses where serological evidence supports diagnosis, surveillance, and retrospective confirmation. Diagnostic laboratories prefer ELISA because it can process multiple samples efficiently and fits established laboratory workflows.

The Arbovirus Testing Market Report highlights ELISA-based tests as a cost-effective and scalable option for hospitals, reference laboratories, and public health agencies. These tests are commonly used when patients present after several days of symptoms, when viral RNA may be harder to detect. The segment also benefits from automation-compatible formats, batch testing capability, and broad availability of commercial kits. However, cross-reactivity remains a technical concern, especially among flaviviruses. Manufacturers are therefore focusing on improved antigen design, better controls, and clearer interpretation protocols. ELISA-based testing continues to support Arbovirus Testing Market Share because it combines accessibility, laboratory familiarity, and surveillance utility.

RT-PCR based tests account for an estimated 38% share of the Arbovirus Testing Market. This segment is growing because molecular diagnostics can detect viral RNA during the early phase of infection, often before antibody responses are fully developed. RT-PCR based tests are highly valuable for acute dengue, Zika, chikungunya, yellow fever, and West Nile virus investigations when rapid confirmation is required. Hospitals and diagnostic laboratories use these tests to improve early clinical decision-making and reduce uncertainty in patients with overlapping symptoms.

The Arbovirus Testing Market Analysis shows that RT-PCR demand is strongest in reference laboratories, advanced hospitals, and outbreak-response settings. Molecular assays are also important for pregnant patients with suspected Zika exposure, severe dengue evaluation, and travel-related febrile illness. The segment benefits from automation, multiplexing, and sample-to-answer platforms. However, adoption may be limited by equipment costs, technical requirements, and the short diagnostic window for some infections. Manufacturers are addressing these issues through lyophilized reagents, cartridge-based systems, and multiplex panels. RT-PCR based tests remain central to Arbovirus Testing Market Growth because they support speed, specificity, and early detection.

To know how our report can help streamline your business, Speak to Analyst

By End-use

Diagnostic laboratories represent an estimated 46% share of the Arbovirus Testing Market. This is the largest end-use segment because reference laboratories and commercial labs handle high-volume testing, confirmatory diagnosis, surveillance support, and specialized arbovirus panels. Many hospitals send complex or low-frequency arbovirus samples to external laboratories because they require validated methods, trained staff, and established quality systems. Diagnostic laboratories also support public health reporting and outbreak investigations.

The Arbovirus Testing Market Research Report shows that diagnostic laboratories are major buyers of ELISA kits, RT-PCR reagents, controls, calibrators, extraction systems, and automation platforms. Their purchasing decisions are shaped by assay accuracy, menu breadth, turnaround time, reagent stability, and technical support. Laboratories also require flexible testing models because arbovirus demand can increase suddenly during outbreaks or travel seasons. B2B suppliers that offer scalable kits, workflow integration, and strong documentation are well positioned in this segment. Diagnostic laboratories remain critical to Arbovirus Testing Market Outlook because they connect clinical care, surveillance, and epidemiological intelligence.

Hospitals hold an estimated 34% share of the Arbovirus Testing Market. Hospital demand is driven by emergency departments, infectious disease units, maternity care, neurology departments, and travel medicine clinics. Patients with fever, rash, joint pain, neurological symptoms, or suspected mosquito-borne exposure often enter the healthcare system through hospitals. Early testing helps physicians distinguish arbovirus infection from bacterial sepsis, malaria, respiratory infections, autoimmune conditions, and other causes of acute illness.

The Arbovirus Testing Industry Report indicates that hospitals increasingly need rapid molecular testing and accessible serology options. Large tertiary hospitals may run RT-PCR based tests in-house, while smaller hospitals rely on send-out testing to diagnostic laboratories. Demand is also increasing for decision-support algorithms that guide test selection based on symptom timing and exposure history. Hospitals are important B2B customers because they need reliable supply contracts, training, and integration with laboratory information systems. Their role in Arbovirus Testing Market Growth is expected to strengthen as vector-borne disease awareness rises among clinicians.

Research centers account for an estimated 20% share of the Arbovirus Testing Market. This segment includes academic institutions, government laboratories, vector-borne disease programs, vaccine research groups, and translational research organizations. Research centers use arbovirus testing for assay development, epidemiology, genomic surveillance, vector studies, vaccine evaluation, and pathogenesis research. Their testing requirements often extend beyond routine clinical diagnosis and may include sequencing, neutralization assays, viral culture, and experimental molecular workflows.

The Arbovirus Testing Market Insights show that research centers influence innovation by validating new biomarkers, improving assay specificity, and studying transmission patterns. They also support regional preparedness by monitoring emerging arboviruses and evaluating diagnostic performance in different populations. Manufacturers benefit from research partnerships because they generate performance data, field validation, and new product opportunities. Although this segment has a smaller market share than hospitals and diagnostic laboratories, it plays a strategic role in Arbovirus Testing Industry Analysis by shaping future testing standards and technology adoption.

Arbovirus Testing Market Regional Outlook

To get more information on the regional analysis of this market, Download Free sample

North America

North America holds an estimated 36% share of the Arbovirus Testing Market. The region is driven by advanced diagnostic infrastructure, strong public health surveillance, hospital-based testing, and reference laboratory networks. West Nile virus testing is a consistent seasonal demand factor, while dengue, Zika, and chikungunya testing are strongly linked to travel-associated cases and localized outbreak concerns. The United States leads regional demand because of its large laboratory base, regulatory focus, and established disease reporting systems.

The Arbovirus Testing Market Outlook in North America is also influenced by climate-related vector expansion and greater clinical awareness of mosquito-borne infections. Public health agencies require reliable testing to guide mosquito control, track disease clusters, and protect blood safety. Hospitals and diagnostic laboratories demand assays that distinguish similar febrile illnesses quickly and accurately. B2B suppliers compete through assay validation, automation compatibility, rapid delivery, and technical support. The region remains a premium market for RT-PCR based tests, ELISA-based tests, multiplex panels, and laboratory-developed testing support.

Europe

Europe accounts for an estimated 27% share of the Arbovirus Testing Market. The region is seeing increased attention to West Nile virus, dengue, chikungunya, and tick-borne arboviruses as vector habitats shift and travel-associated infections rise. Southern and Central European countries are strengthening surveillance, while large reference laboratories support confirmatory testing and outbreak response. The European market benefits from strong regulatory systems, advanced hospital networks, and high-quality diagnostic laboratories.

The Arbovirus Testing Market Analysis in Europe shows increasing demand for multiplex testing and standardized diagnostic algorithms. Public health agencies need consistent data to monitor imported and locally acquired cases. Laboratories are also investing in molecular platforms and automated serology systems to improve capacity during seasonal peaks. B2B buyers in Europe prioritize validated assays, compliance documentation, sample efficiency, and high specificity. The market is competitive, with manufacturers focusing on ELISA-based tests, RT-PCR based tests, and integrated workflows for surveillance-ready diagnostics.

Germany Arbovirus Testing Market

Germany represents an estimated 24% of Europe’s Arbovirus Testing Market. The country has a strong diagnostic laboratory structure, advanced hospital networks, and established infectious disease surveillance capabilities. West Nile virus monitoring has become increasingly important, while dengue, Zika, and chikungunya testing demand is influenced by travel medicine and imported case investigations. German laboratories require high-quality assays with strong specificity because flavivirus cross-reactivity can complicate interpretation.

The Germany Arbovirus Testing Market is supported by research institutions, public health laboratories, and private diagnostic providers. ELISA-based tests remain important for serological confirmation, while RT-PCR based tests are used for early detection and acute infection assessment. B2B opportunities exist for manufacturers offering automated platforms, multiplex panels, and confirmatory testing solutions. Germany’s emphasis on quality systems and laboratory accuracy makes it a strong market for premium diagnostics, validation support, and surveillance-focused Arbovirus Testing Market Insights.

United Kingdom Arbovirus Testing Market

The United Kingdom holds an estimated 19% of Europe’s Arbovirus Testing Market. Demand is driven mainly by travel-related dengue, chikungunya, Zika, and other imported arbovirus infections. Although widespread local mosquito-borne transmission remains limited, clinicians and laboratories maintain testing readiness because international travel, climate shifts, and vector surveillance continue to influence risk perception. The UK market depends heavily on reference laboratory expertise and specialist infectious disease pathways.

The United Kingdom Arbovirus Testing Market is also shaped by strong academic research, travel medicine services, and public health preparedness. Hospitals require clear testing algorithms for febrile travelers, pregnant patients, and suspected neurological complications. Diagnostic laboratories seek accurate RT-PCR based tests for acute cases and ELISA-based tests for later-stage confirmation. B2B suppliers can gain traction by offering reliable panels, education support, and flexible procurement models. The UK remains an important Arbovirus Testing Industry Analysis market because it combines research strength with travel-driven diagnostic demand.

Asia-Pacific

Asia-Pacific accounts for an estimated 29% share of the Arbovirus Testing Market. The region has high testing relevance because dengue, Japanese encephalitis, chikungunya, and other arboviruses are endemic in many countries. Urbanization, dense populations, monsoon patterns, mosquito breeding habitats, and expanding healthcare access contribute to sustained diagnostic demand. Hospitals and diagnostic laboratories across the region need scalable testing solutions for both routine diagnosis and outbreak surges.

The Arbovirus Testing Market Forecast in Asia-Pacific is supported by growing investment in molecular diagnostics, public health laboratories, and local manufacturing. Countries such as China, Japan, India, Singapore, Thailand, Indonesia, and Australia are strengthening arbovirus preparedness. ELISA-based tests are widely used due to affordability and batch-testing suitability, while RT-PCR based tests are expanding in advanced laboratories and outbreak-response centers. B2B suppliers must address pricing sensitivity, distribution reach, regulatory variation, and training needs. Asia-Pacific offers major Arbovirus Testing Market Opportunities for companies that can deliver reliable, cost-efficient, and high-volume testing solutions.

Japan Arbovirus Testing Market

Japan represents an estimated 17% of the Asia-Pacific Arbovirus Testing Market. The country maintains advanced diagnostic infrastructure, strong research capacity, and high public health preparedness. Testing demand is shaped by Japanese encephalitis surveillance, travel-associated dengue and chikungunya cases, and broader interest in emerging infectious disease readiness. Hospitals and reference laboratories emphasize assay quality, automation, and clear clinical interpretation.

The Japan Arbovirus Testing Market benefits from strong laboratory standards and investment in advanced diagnostics. RT-PCR based tests are used in acute and confirmatory settings, while ELISA-based tests support serology and surveillance workflows. Research centers contribute to Arbovirus Testing Market Insights through vector studies, vaccine-related research, and diagnostic innovation. B2B suppliers entering Japan must meet high expectations for documentation, performance, and technical service. The country remains an important premium market for advanced arbovirus diagnostics, especially products that support precision, workflow efficiency, and preparedness planning.

China Arbovirus Testing Market

China accounts for an estimated 33% of the Asia-Pacific Arbovirus Testing Market. The country’s large population, expanding healthcare system, regional dengue risk, and growing molecular diagnostics capacity support strong demand. Public health surveillance, hospital testing, research programs, and local diagnostic manufacturing are all important contributors. China’s diagnostic laboratories increasingly require scalable platforms that can support outbreak response and routine infectious disease testing.

The China Arbovirus Testing Market is also influenced by biotechnology manufacturing strength and increasing investment in domestic assay development. ELISA-based tests remain important for broad screening and serological surveillance, while RT-PCR based tests are expanding in advanced hospitals and public health laboratories. B2B opportunities exist in multiplex testing, reagent supply, automation, and regional distribution. The market is competitive, with demand for cost-efficient products that maintain dependable performance. China plays a central role in Arbovirus Testing Market Size expansion across Asia-Pacific because of its manufacturing capacity, surveillance needs, and growing clinical diagnostics infrastructure.

Rest of World

Rest of World holds an estimated 8% share of the Arbovirus Testing Market. This region includes Latin America, the Middle East, and Africa, where dengue, yellow fever, chikungunya, Zika, Rift Valley fever, and other arboviruses create significant diagnostic needs. Latin America is especially important because dengue outbreaks generate recurring demand for high-volume testing, while parts of Africa and the Middle East require surveillance for multiple vector-borne viruses.

The Arbovirus Testing Market Growth in Rest of World is shaped by public health investment, donor-supported programs, expanding private laboratories, and rising clinical awareness. Many laboratories need affordable ELISA-based tests, rapid screening tools, and practical RT-PCR based tests that can function in variable infrastructure conditions. B2B suppliers must address distribution gaps, training requirements, and procurement cycles. The region offers Arbovirus Testing Market Opportunities for companies that can provide resilient supply chains, simple workflows, and outbreak-ready testing systems.

List of Top Arbovirus Testing Companies

• Abbott
• Thermo Fisher Scientific Inc.
• NovaTec Immundiagnostica GmbH (Gold Standard Diagnostics Frankfurt GmbH)
• Agilent Technologies, Inc.
• EUROIMMUN Medical Laboratory Diagnostics AG
• Merck KGaA
• F. Hoffmann-La Roche Ltd
• Siemens Healthineers AG
• QIAGEN
• Bio-Rad Laboratories, Inc.

Top two companies with the highest market share:

• Abbott: 13.5%
• Thermo Fisher Scientific Inc.: 11.8%

Investment Analysis and Opportunities

Investment in the Arbovirus Testing Market is increasing across molecular diagnostics, serology automation, multiplex panels, and decentralized testing. Companies are investing in product portfolios that support both routine testing and outbreak response. Diagnostic laboratories want systems that can scale quickly during seasonal peaks, while hospitals want faster results for acute patient management. Investors are also focusing on assay manufacturers with strong regulatory pathways, flexible production capacity, and access to endemic markets.

Arbovirus Testing Market Opportunities are strongest in Asia-Pacific, Latin America, and selected parts of North America and Europe where surveillance activity is expanding. New investment is expected in RT-PCR based tests, ELISA-based tests, sample preparation systems, and cloud-connected laboratory reporting. B2B buyers are seeking suppliers that can provide validated assays, technical training, and reliable reagent availability. Companies that combine affordability, accuracy, and workflow simplicity are well positioned. Partnerships with public health programs, hospitals, and research centers can create long-term demand visibility without relying only on outbreak-driven sales.

New Product Development

New product development in the Arbovirus Testing Market focuses on faster, more accurate, and more differentiated diagnosis. Manufacturers are improving RT-PCR based tests with multiplex capability, internal controls, simplified extraction, and stable reagents. These innovations help laboratories identify dengue, Zika, chikungunya, West Nile virus, and other targets from limited sample volumes. Sample-to-answer platforms are also gaining attention because they reduce manual handling and support decentralized testing.

ELISA-based test innovation is centered on improved antigen selection, reduced cross-reactivity, automation compatibility, and clearer result interpretation. Manufacturers are also developing rapid tests and hybrid testing strategies that combine screening with confirmatory workflows. Research centers are exploring sequencing-based surveillance, biosensors, portable molecular platforms, and AI-supported outbreak analytics. The Arbovirus Testing Industry Analysis shows that innovation is moving beyond single-pathogen diagnosis toward broader syndromic testing. Products that improve laboratory productivity, reduce false interpretation, and support public health reporting will shape future Arbovirus Testing Market Trends.

Five Recent Developments (2023-2025)

• Abbott expanded infectious disease diagnostic capabilities with continued emphasis on scalable molecular and immunoassay workflows for outbreak-related testing needs.
• Thermo Fisher Scientific strengthened molecular testing portfolios with advanced PCR instruments, reagents, and workflow solutions suitable for arbovirus research and diagnostic applications.
• QIAGEN advanced sample preparation and molecular testing solutions used by laboratories working on mosquito-borne and emerging infectious disease detection.
• Bio-Rad Laboratories continued expanding quality control, PCR, and immunoassay support tools for clinical laboratories performing infectious disease diagnostics.
• EUROIMMUN and Gold Standard Diagnostics Frankfurt continued supporting serological testing demand through immunoassay portfolios relevant to dengue, Zika, chikungunya, and related arbovirus investigations.

Report Coverage

The Arbovirus Testing Market Report covers diagnostic technologies, assay types, end-use demand, regional performance, market drivers, restraints, challenges, and opportunities. It evaluates ELISA-based tests and RT-PCR based tests across hospitals, diagnostic laboratories, and research centers. The report also examines Arbovirus Testing Market Share by region, country-level dynamics, and B2B purchasing priorities.

Request for Customization   to gain extensive market insights.

The Arbovirus Testing Market Research Report includes analysis of dengue, Zika, chikungunya, West Nile virus, yellow fever, Japanese encephalitis, and related vector-borne viral infections. Coverage includes laboratory workflows, surveillance demand, clinical testing needs, product innovation, and competitive positioning. The Arbovirus Testing Industry Report is designed for manufacturers, distributors, investors, hospitals, public health organizations, and diagnostic service providers. It provides Arbovirus Testing Market Insights into product demand, technology adoption, regional opportunities, and customer needs without using revenue or CAGR figures.